HAIFA, Israel--(BUSINESS WIRE)--March 7, 2005-- Pluristem Life Systems, Inc. (OTCBB: PLRS - News), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that the Company completed private placements aggregating $3.2 million, part of which has been announced in our press release dated January 27, 2005, to further its development efforts, expand the Company's infrastructure and for working capital. Terms will be set out in a Form 8-K to be filed with the Securities and Exchange Commission.

The funds will be utilized to continue development of the Company's proprietary stem cell expansion technology utilizing the PluriX(TM) bioreactor, increase the company's infrastructure to accommodate anticipated growth, make progress towards entry into clinical trials, and continue to explore synergistic strategic alliances.

All shares and warrants issued in this private placement are required to be registered in a registration statement but are subject to agreed upon trading restrictions that remain in place for a period of one-half to one and a half years, as described in the 8-K.

"This interim funding provides working capital that is crucial to maintaining the Company's forward momentum as it strives to achieve its short-term growth objectives. This funding also provides us with the requisite capital to achieve immediate and necessary goals while pursuing a larger funding mechanism that is necessary for our planned entry into the clinical trial process, stated Yossi Keret, CFO.

About Pluristem

Pluristem strives to become a leading biopharmaceutical company developing, producing and marketing stem cell products for cell regenerative therapy. Pluristem's platform for expanding stem cells offers breakthrough technology and multiple product opportunities in many therapeutic areas.

For more information, visit the Company's website at: www.pluristem.com.

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements". including statements regarding our intent, beliefs or current expectations. Forward-looking statements in this release include that the funds will be utilized to continue development of the Company's proprietary stem cell expansion technology utilizing the PluriX(TM) bioreactor, increase the company's infrastructure to accommodate anticipated growth, make progress towards clinical trial activity and continue to explore synergistic strategic alliances, as well as statements regarding the company having sufficient working capital to fulfill its immediate working capital requirements and continue with its stem cell development plan. Actual outcomes and our actual results could differ materially from those in such forward-looking statements, as we may find that working capital is used more quickly than anticipated, we may face unanticipated expenses, we may determine that our funds are needed for other purposes and we may not be able raise funding when we require it.. For further risk factors see the Company's latest 10-KSB filed with the SEC.

---

Contact:

     For Pluristem Life Systems, Inc.
     DeMonte Associates
     Cynthia DeMonte, 212-605-0525
     cdemonte@aol.com